Do vascular lesions and related risk factors influence responsiveness to donepezil chloride in patients with Alzheimer's disease?

Dementia and Geriatric Cognitive Disorders

Volumn 20, Issue 1, 2005, Pages 15-24

  Fukui, Toshiya ^a   Taguchi, Susumu ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Clock drawing test; Donepezil chloride; Therapeutic responsiveness; Vascular lesions; Vascular risk factors

Indexed keywords

DONEPEZIL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRAWING; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; HYPERTENSION; MALE; PATIENT CODING; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RATING SCALE; RISK FACTOR; SAMPLE SIZE; SCORING SYSTEM; VASCULAR LESION;

AGED; ALZHEIMER DISEASE; BRAIN; BRAIN ISCHEMIA; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 22144452207     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085069     Document Type: Article

References (47)

1. Alhainen K, Helkala EL, Reinikainen K, Riekkinen P Sr: The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1993;5:185-192.
2. Schneider LS, Lyness SA, Pawluczyk S, Gleason RP, Sloane RB: Do blood pressure and age predict response to tacrine (THA) in Alzheimer's disease? A preliminary report. Psychopharmacol Bull 1991;27:309-314.
3. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL: Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 1998;50:669-677.
4. Alhainen K, Riekkinen PJ Sr: Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand Suppl 1993;149:16-21.
5. Kaufer DI, Cummings JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
6. Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001;58:417-422.
7. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL: The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388-1393.
8. Mega MS, Dinov ID, Lee L, O'Connor SM, Masterman DM, Wilen B, Mishkin F, Toga AW, Cummings JL: Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2000;12:209-218.
9. Hanyu H, Tanaka Y, Sakurai H, Takasaki M, Abe K: Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease. Neurosci Lett 2002;319:33-36.
10. Pomara N, Deptula D, Singh R: Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease. Psychopharmacol Bull 1991;27:301-307.
11. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease - The Nun Study. JAMA 1997; 277:813-817.
12. Kivipelto M, Laakso MP, Tuomilehto J, Nissinen A, Soininen H: Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: Potential for pharmacological intervention. CNS Drugs 2002;16:435-444.
13. de la Torre JC: Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 2002; 33:1152.
14. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002; 359:1283-1290.
15. Bowler JV: Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Stroke 2003;34:584-586.
16. Kumar V, Anand R, Messina J, Hartman R, Veach J: An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159-169.
17. Erkinjuntti T, Skoog I, Lane R, Andrews C: Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Int J Clin Pract 2002;56:791-796.
18. Freedman M, Leach L, Kaplan E, Winocur G, Shulman KI, Delis DC: Clock Drawing: A Neuropsychological Analysis, ed 1. New York, Oxford University Press, 1994.
19. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH: Clock drawing in Alzheimer's disease: A novel measure of dementia severity. J Am Geriatr Soc 1989;37:725-729.
20. Lieberman D, Galinsky D, Fried V, Grinshpun Y, Mytlis N, Tylis R, Lieberman D: Factors affecting the results of the clock drawing test in elderly patients hospitalized for physical rehabilitation. Int J Geriatr Psychiatry 1999;14: 325-330.
21. Juby A, Tench S, Baker V: The value of clock drawing in identifying executive cognitive dysfunction in people with a normal Mini-Mental State Examination score. CMAJ 2002;167: 859-864.
22. Heinik J, Solomesh I, Bleich A, Berkman P: Are the clock-drawing test and the MMSE combined interchangeable with CAMCOG as a dementia evaluation instrument in a specialized outpatient setting? J Geriatr Psychiatry Neurol 2003;16:74-79.
23. Cahn-Weiner DA, Williams K, Grace J, Tremont G, Westervelt H, Stern RA: Discrimination of dementia with Lewy bodies from Alzheimer disease and Parkinson disease using the clock drawing test. Cogn Behav Neurol 2003; 16:85-92.
24. Powlishta KK, von Dras DD, Stanford A, Carr DB, Tsering C, Miller JP, Morris JC: The clock drawing test is a poor screen for very mild dementia. Neurology 2002;59:898-903.
25. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A: Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
26. World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organization, 1992, pp 50-51.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
28. Hosokawa T, Yamada Y, Isagoda A, Nakamura R: Psychometric equivalence of the Hasegawa Dementia Scale-Revised with the Mini-Mental State Examination in stroke patients. Percept Mot Skills 1994;79:664-666.
29. Rogers SL, Doody RS, Mohs RC, Friedhoff LT: Donepezil improves cognition and global function in Alzheimer disease - A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-1031.
30. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA: MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351-356.
31. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P, European Task Force on Age-Related White Matter Changes: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-1322.
32. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H: Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683-1689.
33. Takao M, Koto A, Tanahashi N, Fukuuchi Y, Takagi M, Morinaga S: Pathologic findings of silent hyperintense white matter lesions on MRI. J Neurol Sci 1999;167:127-131.
34. Takao M, Koto A, Tanahashi N, Fukuuchi Y, Takagi M, Morinaga S: Pathologic findings of silent, small hyperintense foci in the basal ganglia and thalamus on MRI. Neurology 1999;52: 666-668.
35. Pugh KG, Lipsitz LA: The microvascular frontal-subcortical syndrome of aging. Neurobiol Aging 2002;23:421-431.
36. Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K: Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn 1992;18:70-87.
37. Filley CM: The behavioral neurology of cerebral white matter. Neurology 1998;50:1535-1540.
38. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, Breteler MM: Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol 2000;47:145-151.
39. Elias PK, Elias MF, D'Agostino RB, Cupples LA, Wilson PW, Silbershatz H, Wolf PA: NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 1997;20:1388-1395.
40. Hutchison CW, Nathan PJ, Mrazek L, Stough C: Cholinergic modulation of speed of early information processing: The effect of donepezil on inspection time. Psychopharmacology (Berl) 2001;155:440-442.
41. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.
42. Hunter R, Wyper DJ, Patterson J, Hansen MT, Goodwill GM: Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerised tomography. Br J Psychiatry 1991;158:351-357.
43. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC: Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1:426-436.
44. Wood WG, Igbavboa U: Cholesterol trafficking and amyloid beta peptides. Pharmacopsychiatry 2003;36(suppl 2):S144-S148.
45. Eckert GP, Kirsch C, Leutz S, Wood WG, Muller WE: Cholesterol modulates amyloid beta-peptide's membrane interactions. Pharmacopsychiatry 2003;36(suppl 2):S136-S143.
46. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, Girones X, Henry TL, Matsubara E, Zambon D, Wolozin B, Sano M, Cruz-Sanchez FF, Thal LJ, Petanceska SS, Refolo LM: Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003;61:199-205.
47. Mungas D, Jagust WJ, Reed BR, Kramer JH, Weiner MW, Schuff N, Norman D, Mack WJ, Willis L, Chui HC: MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease. Neurology 2001;57:2229-2235.